Yarrow Bioscience (YARW) Change in Receivables (2017 - 2023)
Yarrow Bioscience's (YARW) quarterly Change in Receivables came in at $16000.0 in Q3 2023, down 90.42% YoY from $167000.0 in Q3 2022, and down 87.6% on a QoQ basis from $129000.0 in Q2 2023.
Yarrow Bioscience (YARW) Change in Receivables (2017 - 2023) Analysis & Trends
Yarrow Bioscience (YARW) has 5 years of Change in Receivables data on file, last reported at $16000.0 in Q3 2023.
- Quarterly Change in Receivables fell 90.42% year-over-year to $16000.0 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $244000.0 (up 102.7% YoY) and the FY2018 annual result came in at -$786000.0, down 200.0% from the prior year.
- Change in Receivables retreated to $16000.0 in Q3 2023, from $129000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $798000.0 in Q2 2021 to a low of -$8.0 million in Q1 2022.
- A 3-year average of -$1.5 million and a median of -$68000.0 in 2023 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2022 — Change in Receivables sank 128.95% — and 2023, when it soared 155.84%.
- Tracing YARW's Change in Receivables over 3 years: stood at -$996000.0 in 2021, then jumped by 116.77% to $167000.0 in 2022, then plunged by 90.42% to $16000.0 in 2023.
- The last three Change in Receivables figures came in at $16000.0 (Q3 2023), $129000.0 (Q2 2023), and -$68000.0 (Q1 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Yarrow Bioscience | 31.25 Mn | 8.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 16,000.00 |
| Sep 30, 2023 | 16,000.00 |
| Jun 30, 2023 | 129,000.00 |
| Jun 30, 2023 | 129,000.00 |
| Mar 31, 2023 | -68,000.00 |
| Mar 31, 2023 | -68,000.00 |
| Sep 30, 2022 | 167,000.00 |
| Sep 30, 2022 | 167,000.00 |
| Jun 30, 2022 | -231,000.00 |
| Jun 30, 2022 | -231,000.00 |
| Mar 31, 2022 | -7.98 Mn |
| Mar 31, 2022 | -7.98 Mn |
| Sep 30, 2021 | -996,000.00 |
| Sep 30, 2021 | -996,000.00 |
| Jun 30, 2021 | 798,000.00 |
| Jun 30, 2021 | 798,000.00 |
| Mar 31, 2021 | -5.06 Mn |
| Mar 31, 2021 | -5.06 Mn |
| Sep 30, 2018 | -93,000.00 |
| Sep 30, 2018 | -93,000.00 |